UVicSpace

Controlled release of glial cell line-derived neurotrophic factor from poly (ε-caprolactone) microspheres

Show simple item record

dc.contributor.author Agbay, Andrew
dc.contributor.author Mohtaram, Nima Khadem
dc.contributor.author Willerth, Stephanie
dc.date.accessioned 2016-05-24T12:19:59Z
dc.date.available 2016-05-24T12:19:59Z
dc.date.copyright 2014 en_US
dc.date.issued 2014
dc.identifier.citation Agbay, A., Mohtaram, N.K. & Willerth, S.M. (2014). Controlled release of glial cell line-derived neurotrophic factor from poly (ε-caprolactone) microspheres. Drug Delivery and Translational Research, 4(2), 159-170. en_US
dc.identifier.uri http://dx.doi.org/10.1007/s13346-013-0189-0
dc.identifier.uri http://hdl.handle.net/1828/7310
dc.description.abstract Glial cell line-derived neurotrophic factor (GDNF), a growth factor expressed in the central nervous system, promotes the survival of both dopaminergic and motor neurons, making it a promising candidate for neurodegenerative disease therapy. Although GDNF is currently being evaluated in clinical trials for the treatment of Parkinson’s disease (PD), the current delivery method using catheter implantation has certain limitations in terms of delivering GDNF safely and effectively. As a proof of concept, we encapsulated GDNF into poly(ε-caprolactone) (PCL) microspheres to enable controlled drug release for 25 days. First, microspheres were loaded with bovine serum albumin (BSA) to determine the optimal fabrication conditions necessary to achieve the desired release rates of protein. BSA was then used as a carrier protein to preserve GDNF activity during the fabrication process in the presence of organic solvents. GDNF-encapsulated microspheres were created and characterized using scanning electron microscopy. Next, the in vitro release of GDNF along with microsphere morphology was tracked over 25 days. Finally, the bioactivity of the released GDNF was confirmed using PC12 cells. This work demonstrates the potential of such microspheres for the delivery of bioactive GDNF with the end goal of developing a suitable, clinically relevant formulation for injection to appropriate regions of the brain in PD patients. en_US
dc.description.sponsorship The authors would like to acknowledge support from an NSERC Discovery Grant (S.M.W.) and an NSERC Engage Grant with MedGenesis Therapeutix. They would also like to acknowledge the Advanced Microscopy Facility at the University of Victoria and MedGenesis Therapeutix for their on-going support of this project. en_US
dc.language.iso en en_US
dc.publisher Drug Delivery and Translational Research en_US
dc.subject Glial Cell Line-Derived Neurotrophic Factor (GDNF) en_US
dc.subject Parkinson’s disease (PD) en_US
dc.subject Microspheres en_US
dc.subject Controlled Release en_US
dc.subject Spinal cord injury en_US
dc.title Controlled release of glial cell line-derived neurotrophic factor from poly (ε-caprolactone) microspheres en_US
dc.type Postprint en_US
dc.description.scholarlevel Faculty en_US
dc.description.reviewstatus Reviewed en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search UVicSpace


Browse

My Account

Statistics

Help